On May 4, Marina Litvin, MD, attended and spoke at the Midwest Cystic Fibrosis Consortium, which took place in Kansas City, Missouri. Bringing together cystic fibrosis clinicians and researchers, the event promotes collaboration and discussion on topics surrounding the treatment of the disease. At the consortium, Dr. Litvin gave a speech during the breakout sessions, […]
On May 23, Marina Litvin, MD and colleagues had their work titled “Nutritional considerations for a new era: A CF foundation position paper,” published by the Journal of Cystic Fibrosis. The nutritional landscape of cystic fibrosis is fast-changing, “due in part to widespread use of cystic fibrosis transmembrane regulator highly effective modulator therapy” and prevalence […]
In March, Marina Litvin, MD and collaborators published research titled the “Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis,” in the “Journal of Cystic Fibrosis.” The study’s purpose was to bring definition to the effect that elexacaftor-tezacaftor-ivacaftor (ETI) has on body weight, body mass index (BMI), blood pressure, lipids […]